Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Chad Mire, Demetrius Matassov, Joan B. Geisbert, Theresa E. Latham, Krystle N. Agans, Rong Xu, Ayuko Ota-Setlik, Michael A. Egan, Karla A. Fenton, David K. Clarke, John H. Eldridge, Thomas Geisbert

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.

Original languageEnglish (US)
Pages (from-to)688-691
Number of pages4
JournalNature
Volume520
Issue number7549
DOIs
StatePublished - Apr 30 2015

Fingerprint

Ebolavirus
Attenuated Vaccines
Democratic Republic of the Congo
Primates
Vaccines
Vesicular Stomatitis
Disease Outbreaks
Viruses
Filoviridae
Marburgvirus
Western Africa
Viremia
Macaca
Glycoproteins
Fever

ASJC Scopus subject areas

  • General

Cite this

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. / Mire, Chad; Matassov, Demetrius; Geisbert, Joan B.; Latham, Theresa E.; Agans, Krystle N.; Xu, Rong; Ota-Setlik, Ayuko; Egan, Michael A.; Fenton, Karla A.; Clarke, David K.; Eldridge, John H.; Geisbert, Thomas.

In: Nature, Vol. 520, No. 7549, 30.04.2015, p. 688-691.

Research output: Contribution to journalArticle

Mire, C, Matassov, D, Geisbert, JB, Latham, TE, Agans, KN, Xu, R, Ota-Setlik, A, Egan, MA, Fenton, KA, Clarke, DK, Eldridge, JH & Geisbert, T 2015, 'Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus', Nature, vol. 520, no. 7549, pp. 688-691. https://doi.org/10.1038/nature14428
Mire C, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015 Apr 30;520(7549):688-691. https://doi.org/10.1038/nature14428
Mire, Chad ; Matassov, Demetrius ; Geisbert, Joan B. ; Latham, Theresa E. ; Agans, Krystle N. ; Xu, Rong ; Ota-Setlik, Ayuko ; Egan, Michael A. ; Fenton, Karla A. ; Clarke, David K. ; Eldridge, John H. ; Geisbert, Thomas. / Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. In: Nature. 2015 ; Vol. 520, No. 7549. pp. 688-691.
@article{6a862d73bfdc40879259340de50d7a91,
title = "Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus",
abstract = "The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.",
author = "Chad Mire and Demetrius Matassov and Geisbert, {Joan B.} and Latham, {Theresa E.} and Agans, {Krystle N.} and Rong Xu and Ayuko Ota-Setlik and Egan, {Michael A.} and Fenton, {Karla A.} and Clarke, {David K.} and Eldridge, {John H.} and Thomas Geisbert",
year = "2015",
month = "4",
day = "30",
doi = "10.1038/nature14428",
language = "English (US)",
volume = "520",
pages = "688--691",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7549",

}

TY - JOUR

T1 - Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

AU - Mire, Chad

AU - Matassov, Demetrius

AU - Geisbert, Joan B.

AU - Latham, Theresa E.

AU - Agans, Krystle N.

AU - Xu, Rong

AU - Ota-Setlik, Ayuko

AU - Egan, Michael A.

AU - Fenton, Karla A.

AU - Clarke, David K.

AU - Eldridge, John H.

AU - Geisbert, Thomas

PY - 2015/4/30

Y1 - 2015/4/30

N2 - The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.

AB - The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.

UR - http://www.scopus.com/inward/record.url?scp=84928792708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928792708&partnerID=8YFLogxK

U2 - 10.1038/nature14428

DO - 10.1038/nature14428

M3 - Article

C2 - 25853476

AN - SCOPUS:84928792708

VL - 520

SP - 688

EP - 691

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7549

ER -